ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 724,43
0,78%
DAX
19 906,08
-0,49%
Brent Oil
76,515
0,87%
Bitcoin
98 505,90
1,65%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Spyre Therapeutics Inc (SYRE)

  7. Spyre Therapeutics Inc (SYRE) Actualités

SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SYRE
DateHeureSourceTitreSymboleSociété
18/12/202414h00PR Newswire (US)Spyre Therapeutics Added to the Nasdaq Biotechnology IndexNASDAQ:SYRESpyre Therapeutics Inc
02/12/202423h03PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
02/12/202414h00PR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A AntibodiesNASDAQ:SYRESpyre Therapeutics Inc
25/11/202423h11PR Newswire (US)Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:SYRESpyre Therapeutics Inc
19/11/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
19/11/202422h38Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRESpyre Therapeutics Inc
19/11/202403h18PR Newswire (US)Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common StockNASDAQ:SYRESpyre Therapeutics Inc
18/11/202422h14PR Newswire (US)Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded WarrantsNASDAQ:SYRESpyre Therapeutics Inc
18/11/202422h09Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
18/11/202422h03Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
14/11/202423h50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
12/11/202413h30PR Newswire (US)Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the PotentialNASDAQ:SYRESpyre Therapeutics Inc
11/11/202422h05PR Newswire (US)Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024NASDAQ:SYRESpyre Therapeutics Inc
08/11/202422h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
07/11/202422h14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRESpyre Therapeutics Inc
07/11/202422h05PR Newswire (US)Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
07/11/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRESpyre Therapeutics Inc
30/10/202421h05PR Newswire (US)Spyre Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:SYRESpyre Therapeutics Inc
25/10/202422h28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRESpyre Therapeutics Inc
23/10/202420h10Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SYRESpyre Therapeutics Inc
14/10/202414h00PR Newswire (US)Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and CombinationsNASDAQ:SYRESpyre Therapeutics Inc
03/10/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SYRESpyre Therapeutics Inc
02/10/202400h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
01/10/202414h00PR Newswire (US)Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical OfficerNASDAQ:SYRESpyre Therapeutics Inc
20/09/202422h05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SYRESpyre Therapeutics Inc
10/09/202422h47PR Newswire (US)Spyre Therapeutics to Participate in Upcoming Investor ConferenceNASDAQ:SYRESpyre Therapeutics Inc
07/08/202422h05PR Newswire (US)Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
18/07/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
18/06/202413h30PR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseNASDAQ:SYRESpyre Therapeutics Inc
29/05/202414h30PR Newswire (US)Spyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SYRESpyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SYRE

Dernières Valeurs Consultées

BIT
UNI
Unipol Assicurazioni
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés